MonumenTAL-1: Efficacy and Safety Data
Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.
Video content above is prompted by the following:
- How do the overall response rates (ORRs) in both naive and previously exposed patients impact the potential use of this treatment in clinical practice?
- Please comment on the safety results seen in the LTFU MonumenTAL-1 data.
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
